Blockchain Registration Transaction Record

AcroMeta Partners to Revolutionize Cell Logistics with ATCLS Technology

AcroMeta Group acquires stake in Macro-ATCLS to bring ambient temperature cellular logistics to Southeast Asia, targeting a US$14.5B market by 2032.

This strategic partnership positions AcroMeta at the forefront of a transformative shift in cell and gene therapy logistics. By investing in ATCLS, which enables ambient-temperature transport of living cells, the company stands to disrupt a market currently reliant on expensive and fragile cold chains. This move could significantly lower costs and expand access to life-saving therapies across Southeast Asia, potentially accelerating the adoption of advanced treatments like CAR-T and regenerative medicine. For shareholders, it offers a diversification into a high-growth sector, while for the healthcare industry, it heralds a new era of efficient and scalable distribution of biological materials.